Premium
Cyclin‐Dependent Kinase Inhibition With Roscovitine: Neuroprotection in Acute Ischemic Stroke
Author(s) -
Timsit S,
Menn B
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.312
Subject(s) - neuroprotection , medicine , stroke (engine) , thrombolysis , clinical trial , ischemic stroke , clinical pharmacology , pharmacology , intensive care medicine , ischemia , myocardial infarction , mechanical engineering , engineering
Stroke is the third most common cause of mortality and the leading cause of disability in industrialized country. According to population based–studies, ischemic stroke accounts for 67–80% of all strokes. 1 Thrombolysis is used during the acute phase in only 2–5% of ischemic patients. 2 Clinical trials of candidate neuroprotective agents have failed to identify viable therapies for ischemic stroke in humans. 3 There is therefore a great need for new therapeutic strategies, considering that not all brain cells die immediately after ischemic stroke. Clinical Pharmacology & Therapeutics (2012); 91 2, 327–332. doi: 10.1038/clpt.2011.312